임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 1/2상모집 중· Malignant NeoplasmA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Lymphoma, Non-HodgkinA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
리드: 머크(MSD)
- 1/2상모집 중· Lung Neoplasm MalignantA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
리드: 머크(MSD)
- 1/2상모집 중· Locally Advanced or Metastatic Solid TumorsBC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Oesophageal Squamous Cell CarcinomaA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
리드: 머크(MSD)
- 1/2상모집 중· Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaA Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
협력: 머크(MSD)
- 1/2상모집 중· Small Cell Lung Cancer Extensive StageA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
리드: 머크(MSD)
- 1/2상모집 중· Bladder CancerA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
리드: 머크(MSD)
- 1/2상모집 중· Solid TumorsABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Esophageal Squamous Cell CarcinomaSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
리드: 머크(MSD)
- 1/2상모집 중· Cervical AdenocarcinomaExternal Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
협력: 머크(MSD)
- 1/2상모집 중· Castration-Resistant Prostatic CancerA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
리드: 머크(MSD)
- 1/2상모집 중· Malignant NeoplasmA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Ovarian Cancer RecurrentA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
리드: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorsPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Bladder CancerEnfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorsA Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
리드: 머크(MSD)
- 1/2상모집 중· Non-Muscle Invasive Bladder CancerA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
리드: 머크(MSD)
- 1/2상모집 중· Gastrointestinal CancerStudy of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
리드: 머크(MSD)
- 1/2상모집 중· Non-small Cell Lung CancerA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
협력: 머크(MSD)
- 1/2상모집 중· B-cell Acute Lymphoblastic LeukemiaSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Gastroesophageal JunctionSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
리드: 머크(MSD)
- 1/2상모집 중· Extensive Stage-small Cell Lung CancerA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
협력: 머크(MSD)
- 1/2상모집 중· Colorectal CancerA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
리드: 머크(MSD)
- 1/2상모집 중· Prostatic Neoplasms, Castration-ResistantSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
리드: 머크(MSD)
- 1/2상모집 중· Metastatic Breast CancerA Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중· HPV Positive Oropharyngeal Squamous Cell CarcinomaSafety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorPembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중· Esophageal Squamous Cell CarcinomaA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
리드: 머크(MSD)
- 1/2상모집 중· Solid Tumor, AdultA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
협력: 머크(MSD)
- 1/2상모집 중· Gastric or Gastroesophageal Junction AdenocarcinomaSpevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
협력: 머크(MSD)
- 1/2상모집 중· Solid TumorStudy of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Advanced CancerHighly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Advanced/Metastatic Solid TumorsADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Solid TumorsS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Locally Advanced or Metastatic HER2-Expressing CancersTo Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
협력: 머크(MSD)
- 1/2상모집 중· Glioblastoma MultiformeTrial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
협력: 머크(MSD)
- 1/2상모집 중· CancerPhase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorGI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Advanced MalignanciesBI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
협력: 머크(MSD)
- 1/2상모집 중· Primary Central Nervous System LymphomaPembrolizumab, Ibrutinib and Rituximab in PCNSL
협력: 머크(MSD)
- 1/2상모집 중· Solid Tumor, AdultA Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Carcinoma, Non-Small-Cell LungKEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
리드: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorStudy of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.